Abstract
Primary ovarian insufficiency (POI) refers to the ovarian loss of function under the age of 40 years and lead those patients to amenorrhea and infertility. Our previous study showed that transplantation of human bone marrow-derived mesenchymal stem cells (hBM-MSC) in chemotherapy-induced POI mouse ovary can reverse POI through correction of serum hormonal levels, promote follicular generation in the ovary, increase in granulosa cells population, and achieve pregnancy. According to this research, BM-MSC is a promising cell source to treat POI patients, however, there are still concerns about the potential risks of stem cell engraftment due to the route of administration.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
